secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silence Therapeutics plc (SLN)
CIK:        0001479615
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001193125-26-092578
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silence Therapeutics FY 2025 net loss $88.6M; top-line divesiran data on-track for Q3 2026
--------------------------------------------------------------------------------

- Net loss widened to $88.6M ($0.63/share) from $45.3M ($0.33/share) in FY 2024.
- Collaboration revenue dropped to $0.6M from $43.3M; R&D spend flat at $67.8M.
- Cash and investments $85.1M as of Dec 31, 2025; key Phase 2 SANRECO topline due Q3 2026.
- AstraZeneca will not develop SLN312 beyond Phase 1; Silence regains global rights.
- CEO search underway after former CEO departure in Dec 2025; Iain Ross interim.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479615/000119312526092578/0001193125-26-092578-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479615/000119312526092578/sln-20260305.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-092578

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer